ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway
Science Advances · 2026
DOI: 10.1126/sciadv.aed7566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Qiu-Sha Huang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. Hauptthemen laut MEDLINE: Phosphotransferases (Alcohol Group Acceptor), Hypoxia-Inducible Factor 1, alpha Subunit, Lysophospholipids, Tretinoin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China to XHZ, Beijing Natural Science Foundation to QSH.
Abstract (Originalsprache)
Our previous clinical studies show that all-trans retinoic acid (ATRA) induces a sustained response in patients with immune thrombocytopenia (ITP). However, its mechanisms of action remain unclear. In this study, we observed disorganized cytoskeleton and impaired proplatelet formation (PPF) in megakaryocytes from patients with ITP. Metabolite profiling revealed reduced sphingosine 1-phosphate (S1P) levels in ITP. Decreased sphingosine kinase 2 (SPHK2) expression was responsible for the low S1P levels in ITP. In addition, S1P was essential for activating S1P receptor 1 and Rac1, which regulate cytoskeletal reorganization and PPF. Furthermore, hypoxia-inducible factor-1α (HIF-1α) was shown to mediate SPHK2 and S1P production. Decreased HIF-1α expression in megakaryocytes from patients with ITP contributed to impaired PPF. We subsequently found that ATRA up-regulated HIF-1α and corrected impaired PPF in vitro and in vivo. These findings reveal that ATRA targets the HIF-1α/SPHK2/S1P pathway to improve PPF dysfunction, offering mechanistic insights into its clinical efficacy in ITP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
- National Clinical Research Center for Hematologic Disease, Beijing, China.
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
- Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
- Department of Hematology, Qilu Hospital, Jinan, China.
- Chinese Academy of Sciences (CAS) Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, CAS, Beijing, China.
ORCID-Profile: Qiu-Sha Huang, Feng-Qi Liu, Xue-Yan Sun, Xiao-Jun Huang, Xiao-Hui Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China to XHZ
- Beijing Natural Science Foundation to QSH
Zitieren
APA
Huang, Q. S., Xue, J., Liu, F. Q., Chen, Q., Zhang, G., Sun, X. Y., Wang, C., Yang, L., Hou, Y., Li, Y., Wang, Q., Peng, J., Hou, M., Zhao, X., Kong, Y., Chang, Y., Zhao, X., Huang, X. J., & Zhang, X. H. (2026). ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway. Science Advances. https://doi.org/10.1126/sciadv.aed7566
Vancouver
Huang QS, Xue J, Liu FQ, Chen Q, Zhang G, Sun XY, et al. ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway. Science Advances. 2026. doi:10.1126/sciadv.aed7566
BibTeX
@article{Huang2026,
author = {Huang, Qiu-Sha and Xue, Jing and Liu, Feng-Qi and Chen, Qi and Zhang, Gaochao and Sun, Xue-Yan and Wang, Chencong and Yang, Liping and Hou, Yu and Li, Yueying and Wang, Qianfei and Peng, Jun and Hou, Ming and Zhao, Xiaosu and Kong, Yuan and Chang, Yingjun and Zhao, Xiangyu and Huang, Xiao-Jun and Zhang, Xiao-Hui},
title = {ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed7566}
}
EUVIMED